Harrow posts record Q3 revenue, cuts 2026 Adjusted EBITDA outlookNov 9Quarterly updatechloroprocaine hydrochloride ophthalmic gelHarrow Inc
Viatris to acquire Pacira BioSciences for $36.50 per share in cashOct 8M&APacira Pharmaceuticals, IncViatris Inc.
Harrow registers Phase 3 trial of TRIESENCE for pain and inflammation after eye surgerySep 22Trial updateHarrow Inctriamcinolone acetonide
Harrow reports Q2 2026 results, reiterates full-year guidance, cites pipeline progressAug 10Quarterly updateHarrow Inc